Source-grounded facts extracted from CLOVER HEALTH INVESTMENTS, CORP. /DE's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Brady Priest departed as Chief Executive Officer of Clover Care Services at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“On June 15, 2026, Brady Priest notified Clover Health Investments, Corp. (the “Company”) of his decision to step down from his position as Chief Executive Officer of Clover Care Services, the Company’s home-care business, effective as of July 3, 2026.”
CLOVER HEALTH INVESTMENTS, CORP. /DE shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-10 meeting.
“Proposal 3: Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the vote were as follows: FOR AGAINST ABSTAIN 1,188,467,663 2,471,606 1,391,903”
CLOVER HEALTH INVESTMENTS, CORP. /DE shareholders approved Non-binding advisory vote to approve the compensation of the Company's Named Executive Officers for 2025 at the 2026-06-10 meeting.
“Proposal 2: Non-binding advisory vote to approve the compensation of the Company's Named Executive Officers for 2025. The stockholders vote to approve, on a non-binding advisory basis, the compensation of the Company's Named Executive Officers for 2025. The results of the vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTE 1,003,065,402 9,811,825 1,663,812 177,790,033”
CLOVER HEALTH INVESTMENTS, CORP. /DE shareholders approved Election of Three Class II Directors at the 2026-06-10 meeting.
“Proposal 1: Election of Three Class II Directors. Demetrios L. Kouzoukas, Andrew Toy and Thomas L. Tran were each elected to the Company’s Board of Directors as Class II directors, to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The results of the election were as follows: FOR WITHHELD BROKER NON-VOTE Demetrios L. Kouzoukas 1,003,131,251 11,409,888 177,790,033 Andrew Toy 1,011,117,814 3,423,325 177,790,033 Thomas L. Tran 996,918,879 17,622,260 177,790,033”
CLOVER HEALTH INVESTMENTS, CORP. /DE reported the first quarter ended March 31, 2026 results: revenue $749 million, net income $27 million. Guidance reaffirmed.
“First quarter 2026 GAAP Net Income of $27 million, an improvement of $29 million year-over-year • First quarter 2026 Medicare Advantage membership of 155,773, up 51% year-over-year, and Total revenues of $749 million, up 62% year-over-year”
Lee A. Shapiro departed as Director at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“Mr. Shapiro will fulfill the remainder of his term as member of the Board of Directors and the effective date of his departure will be the Company’s Annual Meeting of Shareholders, June 10, 2025.”
Thomas L. Tran was appointed as Class II director at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“On August 20, 2024, the Board of Directors (the "Board") of Clover Health Investments, Corp. ("Clover" or the "Company") appointed Thomas L. Tran, to serve as a Class II director of the Board.”
CLOVER HEALTH INVESTMENTS, CORP. /DE reported the first quarter ended March 31, 2024 results: revenue $346.9 million, net income $23.2 million. Guidance raised.
“exceeding its expectations on several key operating metrics and highlighting significant progress on its path to profitability. For the first quarter 2024, total revenue was $346.9 million, with GAAP net loss from continuing operations improving to $23.2 million. Adjusted EBITDA improved to a profit of $6.8 million, as compared to the prior year period loss of”
Terrence Ronan departed as Interim Chief Financial Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“Mr. Kuipers will succeed Terrence Ronan, the Company’s current Interim Chief Financial Officer, who will continue in his role as Interim Chief Financial Officer until Mr. Kuipers becomes Chief Financial Officer, and thereafter cease to serve as the Company’s principal financial officer and principal accounting officer.”
Peter Kuipers was appointed as Chief Financial Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“On April 22, 2024, Clover Health Investments, Corp. (the “Company”) announced that Peter Kuipers will become Chief Financial Officer of the Company, to serve as the Company’s principal financial officer and principal accounting officer, effective as of the day after the filing of the Company’s Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024, as approved by the Board of Directors of the Company on April 16, 2024.”
CLOVER HEALTH INVESTMENTS, CORP. /DE received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“April 2, 2024, Clover Health Investments, Corp. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s Class A common stock (the “Common Stock”) had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Notice has no immediate effect on the listing of the Common Stock, which continues to trade on”
CLOVER HEALTH INVESTMENTS, CORP. /DE reported fourth quarter and full year ended December 31, 2023 results: revenue $510.3 million, net income net loss of $70.5 million. Guidance initiated.
“will host a conference call today at 5:00 p.m. ET to discuss its operating results and other business highlights. For the fourth quarter 2023, the Company reported revenue of $510.3 million and net loss of $70.5 million, with full-year revenue of $2,033.7 million and net loss of $213.4 million. Adjusted EBITDA during 2023 improved to a loss of $19.1 million in the”
Scott J. Leffler departed as Chief Financial Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“following Scott J. Leffler’s previously announced departure as Chief Financial Officer.”
Terrence Ronan was appointed as Interim Chief Financial Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“On December 22, 2023, the Board of Directors of Clover Health Investments, Corp. (the “Company”) appointed Mr. Terrence Ronan as Interim Chief Financial Officer, including as principal financial officer and principal accounting officer, effective as of January 27, 2024.”
Scott J. Leffler departed as Chief Financial Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“On December 15, 2023, Scott J. Leffler notified Clover Health Investments, Corp. (the “Company”) that he will be stepping down as Chief Financial Officer of the Company, including as principal financial officer and principal accounting officer, effective as of January 26, 2024, in order to pursue another professional opportunity.”
CLOVER HEALTH INVESTMENTS, CORP. /DE announced a impairment with charges of approximately $6 million.
“the Company expects to record a non-cash impairment charge in the fourth quarter of 2023 of its assets in an estimated amount of approximately $6 million.”
CLOVER HEALTH INVESTMENTS, CORP. /DE announced a restructuring with charges of approximately $8 million to $10 million affecting ACO REACH Program.
“the Company expects to incur total charges related to the exit from the ACO REACH Program of approximately $8 million to $10 million, the majority of which are non-cash in nature as described in Item 2.06 below. These charges also include severance costs and legal costs, some of which may result in future cash expenditures. Exit activities are expected to conclude by the end of 2024.”
CLOVER HEALTH INVESTMENTS, CORP. /DE reported the third quarter 2023 results: revenue $482.1 million, net income net loss of $41.5 million. Guidance reaffirmed.
“For the third quarter 2023, the Company reported revenue of $482.1 million and net loss of $41.5 million.”
CLOVER HEALTH INVESTMENTS, CORP. /DE reported the quarter ended June 30, 2023 results: revenue $513.6 million, net income $28.8 million. Guidance reaffirmed.
“For the second quarter 2023, the Company reported revenue of $513.6 million and net loss of $28.8 million.”
CLOVER HEALTH INVESTMENTS, CORP. /DE shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-07 meeting.
“Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the vote were as follows: For Against Abstain 1,074,118,616 3,280,363 1,717,575”
CLOVER HEALTH INVESTMENTS, CORP. /DE shareholders approved Non-binding advisory vote to approve the compensation of the Company's Named Executive Officers for 2022 at the 2023-06-07 meeting.
“Non-binding advisory vote to approve the compensation of the Company's Named Executive Officers for 2022: The stockholders vote to approve, on a non-binding advisory basis, the compensation of the Company's Named Executive Officers for 2022. The results of the vote were as follows: For Against Abstain Broker Non-Votes 938,847,123 15,400,898 1,440,947 123,427,586”
CLOVER HEALTH INVESTMENTS, CORP. /DE shareholders approved Election of 2 Class II directors at the 2023-06-07 meeting.
“The results of the election were as follows: Nominee For Withheld Broker Non-Votes Demetrios L Kouzoukas 937,464,810 18,224,158 123,427,586 Andrew Toy 939,487,709 16,201,259 123,427,586”
Joseph Martin departed as General Counsel and Corporate Secretary at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“On June 5, 2023, Joseph Martin notified Clover Health Investments, Corp. (the “Company”) that he will be resigning as General Counsel and Corporate Secretary of the Company, effective as of June 16, 2023, in order to pursue a new role at a public company.”
CLOVER HEALTH INVESTMENTS, CORP. /DE reported full year 2023 results: revenue Insurance revenue of $1.18 billion - $1.23 billion. Guidance raised.
“Improved 2023 guidance includes Insurance MCR of 87% - 89%, Insurance revenue of $1.18 billion - $1.23 billion, and Adjusted EBITDA of ($125) million - ($175) million”
CLOVER HEALTH INVESTMENTS, CORP. /DE reported the first quarter 2023 results: revenue $527.8 million, net income net loss of $72.6 million. Guidance raised.
“For the first quarter 2023, the Company reported revenue of $527.8 million and net loss of $72.6 million.”
CLOVER HEALTH INVESTMENTS, CORP. /DE received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“April 20, 2023, Clover Health Investments, Corp. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s Class A common stock (the “Common Stock”) had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Notice has no immediate effect on the listing of the Common Stock, which continues to trade o”
CLOVER HEALTH INVESTMENTS, CORP. /DE announced a restructuring with charges of approximately $7.0 to $9.0 million affecting core plan operations and corporate restructuring (approximately 10% of the Company’s workforce).
“resulted in the elimination of approximately 10% of the Company’s workforce. The Company expects to record total charges related to the initiatives of approximately $7.0 to $9.0 million, primarily all of which will result in future cash expenditures. These charges are expected to be recorded in the first and second quarters of 2023, and to”
CLOVER HEALTH INVESTMENTS, CORP. /DE reported the fiscal year ended December 31, 2022 results: revenue $ 3,476.7, net income (338.8). Guidance initiated.
“Total revenue $ 898.8 $ 432.0 $ 3,476.7 $ 1,472.0 Insurance MCR 92.4 % 102.8 % 91.8 % 106.0 % Non-Insurance MCR 103.6 103.0 103.4 105.7 Salaries and benefits plus General and administrative expenses ("SG&A") (1) $ 124.3 $ 114.1 $ 486.6 $ 445.7 Adjusted Salaries and benefits plus General and administrative expenses ("Adjusted SG&A") (non-GAAP) (1)(2)(3) 85.6 77.5 320.7 264.4 Net loss (84.0) (187.2) (338.8) (587.8)”
CLOVER HEALTH INVESTMENTS, CORP. /DE reported the fourth quarter ended December 31, 2022 results: revenue $ 898.8, net income (84.0). Guidance initiated.
“Total revenue $ 898.8 $ 432.0 $ 3,476.7 $ 1,472.0 Insurance MCR 92.4 % 102.8 % 91.8 % 106.0 % Non-Insurance MCR 103.6 103.0 103.4 105.7 Salaries and benefits plus General and administrative expenses ("SG&A") (1) $ 124.3 $ 114.1 $ 486.6 $ 445.7 Adjusted Salaries and benefits plus General and administrative expenses ("Adjusted SG&A") (non-GAAP) (1)(2)(3) 85.6 77.5 320.7 264.4 Net loss (84.0) (187.2) (338.8) (587.8)”
Prabhdeep Singh departed as Chief Growth Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“On January 20, 2023, Prabhdeep Singh notified Clover Health Investments, Corp. (the "Company") that he will be stepping down from his position as Chief Growth Officer of the Company, effective March 31, 2023.”
Jamie L. Reynoso was appointed as Chief Executive Officer of Medicare Advantage at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“On January 6, 2023, the Board of Directors of Clover Health Investments, Corp. (the " Company ") appointed Jamie L. Reynoso Chief Executive Officer of Medicare Advantage, effective immediately.”
Anna Loengard, M.D. was appointed as Class I director at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“On November 28, 2022, the Board of Directors (the "Board") of Clover Health Investments, Corp. ("Clover" or the "Company") appointed Anna Loengard, M.D., to serve as a Class I director of the Board.”
CLOVER HEALTH INVESTMENTS, CORP. /DE reported third quarter of 2022 results: revenue $ 856.8, net income (75.3).
“Dollars in Millions Q3'22 Q3'21 Total revenue $ 856.8 $ 427.2”
Andrew Toy changed role as Co-Founder and CEO at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“Andrew Toy, the Company’s current President, will be promoted to the position of Co-Founder and CEO and will no longer serve as President”
Vivek Garipalli changed role as Executive Chairman at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“Vivek Garipalli, the Company’s Co-Founder and Chief Executive Officer (“ CEO ”), will become the Executive Chairman of the Board and leave his position as CEO”
Carladenise Armbrister Edwards was appointed as Class III director at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“On July 22, 2022, the Board of Directors (the "Board") of Clover Health Investments, Corp. ("Clover" or the "Company") appointed Carladenise Armbrister Edwards, Ph.D., Executive Vice President and Chief Strategy Officer of the Henry Ford Health System, to serve as a Class III director of the Board and as a member of the Talent and Compensation Committee and the Nominating and Corporate Governance Committee of the Board.”
Nathaniel S. Turner resigned as member of the Board of Directors at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“On May 26, 2022, Nathaniel S. Turner resigned as a member of the Board of Directors of Clover Health Investments, Corp.”
Mark C. Herbers changed role as Interim Chief Financial Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“Mr. Leffler will succeed Mark C. Herbers, the Company’s current Interim Chief Financial Officer, who will continue in his role as Interim Chief Financial Officer until Mr. Leffler joins the Company and thereafter will assist in the transition.”
Scott J. Leffler was appointed as Chief Financial Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“Scott J. Leffler will become Chief Financial Officer of the Company, to serve as the Company’s principal financial officer and principal accounting officer, effective upon the commencement of his employment with the Company in August 2022.”
Karen Soares was appointed as Interim General Counsel at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“Effective on January 19, 2022, and until a permanent replacement for Ms. Lee has been named, Karen Soares, the Company’s Deputy General Counsel, will serve as the Company’s Interim General Counsel.”
Gia Lee departed as General Counsel at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“Gia Lee, the Company’s General Counsel, will be stepping down as an officer of the Company today.”
Mark Herbers was appointed as interim Chief Financial Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“On August 13, 2021, the Company’s Board of Directors appointed Mr. Herbers as interim Chief Financial Officer of the Company, to serve as the Company’s principal financial officer and principal accounting officer.”
Joseph Wagner departed as Chief Financial Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“On July 15, 2021, Clover Health Investments, Corp. (the “Company”) announced that Joseph Wagner, the Company’s Chief Financial Officer, would be stepping down as an officer of the company on August 13, 2021 (the “Departure Date”).”
Mark Herbers was appointed as Interim Chief Financial Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“Effective upon the Departure Date, and until a permanent replacement for Mr. Wagner has been named, Mark Herbers will serve as the Company’s interim Chief Financial Officer.”
Joseph Wagner departed as Chief Financial Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“On July 15, 2021, Clover Health Investments, Corp. (the “Company”) announced that Joseph Wagner, the Company’s Chief Financial Officer, will be stepping down as an officer of the Company on August 13, 2021 (the “Departure Date”), following the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 (the “Second Quarter 2021 Form 10-Q”), for personal reasons.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.